Evidence mapPaperPMID 37265696Full record

ReviewFrontiers in endocrinology2023

Telemedicine for diabetes management during COVID-19: what we have learnt, what and how to implement.

Laszlo Rosta, Adrienn Menyhart, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino and 17 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. The influence of telemedicine in primary healthcare on diabetes mellitus control and treatment adherence in Riyadh region.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 20 institutions in 16 countries.

Laszlo RostaPrimary Healthcare Centre, Felsorajk, Hungary.
Adrienn MenyhartDepartment of Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Wael Al MahmeedHeart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
Khalid Al-RasadiMedical Research Center, Sultan Qaboos University, Muscat, Oman.
Kamila Al-AlawiDepartment of Training and Studies, Royal Hospital, Ministry of Health, Muscat, Oman.
Maciej BanachDepartment of Preventive Cardiology and Lipidology , Medical University of Lodz (MUL), Lodz, Poland.
Yajnavalka BanerjeeDepartment of Biochemistry, Mohammed Bin Rashid University, Dubai, United Arab Emirates.
Antonio CerielloIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy.
Mustafa CesurClinic of Endocrinology, Ankara Güven Hospital, Ankara, Türkiye.
Francesco CosentinoUnit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Stockholm, Sweden.
Alberto FirenzeUnit of Research and International Cooperation, University Hospital of Palermo, Palermo, Italy.
Massimo GaliaDepartment of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Palermo, Italy.
Su-Yen GohDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.
Andrej JanezDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.
Sanjay KalraDepartment of Endocrinology, Bharti Hospital, Karnal, India.
Nitin KapoorDepartment of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India.
Nader LessanThe Research Institute, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.
Paulo LotufoCenter for Clinical and Epidemiological Research, University Hospital, University of São Paulo, Sao Paulo, Brazil.
Nikolaos PapanasDiabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
Ali A RizviDepartment of Medicine, University of Central Florida College of Medicine, Orlando, FL, United States.
Amirhossein SahebkarApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Raul D SantosHeart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.
Anca Pantea StoianFaculty of Medicine, Diabetes, Nutrition and Metabolic Diseases, Carol Davila University, Bucharest, Romania.
Peter P TothCicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Vijay ViswanathanDepartment of Medicine, Diabetes Research Centre, Chennai, India.
Peter KemplerDepartment of Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Manfredi RizzoDepartment of Biochemistry, Mohammed Bin Rashid University, Dubai, United Arab Emirates.
Carol Davila University of Medicine and Pharmacy · ROSemmelweis University · HUUniversity of Palermo · ITBharti Hospital · INChristian Medical College & Hospital · INGüven Hospital · TRHospital São Paulo · BRImperial College London Diabetes Centre · AEIstituti di Ricovero e Cura a Carattere Scientifico · ITJohns Hopkins University · USKarolinska University Hospital · SELjubljana University Medical Centre · SIMashhad University of Medical Sciences · IRMinistry of Health · OMMohammed Bin Rashid University of Medicine and Health Sciences · AENational Healthcare Service Center · HUSingapore General Hospital · SGSultan Qaboos University · OMUniversidade de São Paulo · BRUniversity Hospital of Alexandroupolis · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The past two decades have witnessed telemedicine becoming a crucial part of health care as a method to facilitate doctor-patient interaction. Due to technological developments and the incremental acquisition of experience in its use, telemedicine's advantages and cost-effectiveness has led to it being recognised as specifically relevant to diabetology. However, the pandemic created new challenges for healthcare systems and the rate of development of digital services started to grow exponentially. It was soon discovered that COVID-19-infected patients with diabetes had an increased risk of both mortality and debilitating sequelae. In addition, it was observed that this higher risk could be attenuated primarily by maintaining optimal control of the patient's glucose metabolism. As opportunities for actual physical doctor-patient visits became restricted, telemedicine provided the most convenient opportunity to communicate with patients and maintain delivery of care. The wide range of experiences of health care provision during the pandemic has led to the development of several excellent strategies regarding the applicability of telemedicine across the whole spectrum of diabetes care. The continuation of these strategies is likely to benefit clinical practice even after the pandemic crisis is over.

Indexed as

COVID-19Diabetes MellitusTelemedicineDelivery of Health CareHumansCOVID - 19diabetes carediabetes prevention and controlglucose monitoringtelemedicinetype-2 diabetes (T2DM)

Identifiers

PMID37265696
PMCPMC10231679
OpenAlexW4376875536

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.